Design, Synthesis and Evaluation of 4-Aminopyridine Analogues as Cholinesterase Inhibitors for Management of Alzheimer’s Diseases

ABSTRACT

Introduction: Alzheimer’s disease (AD) is a slowly progressive devasting neurodegenerative disorder of central nervous system manifested by deterioration of memory, cognitive functions, behaviour change and impairment in performing activities of daily life. Neurochemical studies of patients suffering from AD demonstrate selective loss of cholinergic neurons, low concentration of acetylcholine (Ach) in the selective areas of brain such as cortex and hippocampus. Objective: A series of new semicarbazones of 4-aminopyridine has been designed, synthesized and evaluated for cognition enhancing activities through the inhibition of acetylcholinesterase (AChE) and by passive avoidance model. Material and methods: In the present study, ten new 4-Aminopyridine analogues were synthesized and characterized by analytic methods such as UV, IR, NMR, elemental analysis and for their inhibitory role on Acetylcholinesterase activity by applying the molecular docking studies and performed enzyme kinetics study by Ellman’s spectrophotometric method. The synthesized analogues were then evaluated for antiamnesic and cognition enhancing activities by passive avoidance test. Results: The results illustrated a significant cognition enhancing effect on passive avoidance test with a significant reversal of scopolamine-induced amnesia, which is comparable with standard drug rivastigmine. The in-vitro study of synthesized analogues showed maximum activity of compound-3 and compound-9 compared to standard drug rivastigmine, whereas its enzyme kinetic study revealed a non-competitive inhibition of acetylcholinesterase (AChE) is held responsible to a possible interaction of analogue with the peripheral anionic site (PAS) of AChE and was also confirmed by molecular docking studies. Conclusion: On the basis of present study, we are concluding that hydroxyl substituted Compound 3 and 9 identified as most potent drug which can leads to the discovery and development of new Cognition enhancers in near future.

KEYWORDS

• 4-aminopyridine
• Acetylcholinesterase
• Passive avoidance test
• Rivastigmine

Showing references and in-text citations exactly as published.

• DOI10.5530/ijper.52.4.75Copy

RELATED ARTICLES

Matched on section and article type within this issue of IJPER.

• Article · VOLUME 52, ISSUE 4My Opinions Matter! How Perspectives, Knowledge and Expectations Matter in Moderating the Success of New Pharmaceutical Services Implementation in MalaysiaChristine Liang Hoay Tan, Vincent Beng Yong Gan, Fahad Saleem, Mohamed Azmi Ahmad Hassali · pp. 558–574Original ArticleSame type: Article
• Article · VOLUME 52, ISSUE 4Presentation and Quality Evaluation of a Novel Learning Method for Pharmacy Students in Drug Information CourseKaveh Eslami, Leila Kouti, Maryam Aghakouchakzadeh, Mina Khezrian, Mandana Izadpanah · pp. 575–580Original ArticleSame type: Article
• Article · VOLUME 52, ISSUE 4Design, Development and Characterization of Nano Structured Lipid Carrier for Topical Delivery of AceclofenacNaglakshmi Sethuraman, Shanmuganathan S, Sandhya K, Anbarasan B · pp. 581–586Original ArticleSame type: Article
• Article · VOLUME 52, ISSUE 4Comparative Single Dose Pharmacokinetics and Bioavailability Studies of Saquinavir, Ritonavir and their Optimized Cyclodextrin Complexes after Oral Administration into Rats using LC-MS/MS.Bharani S Sogai, Vikram B Narayansetty, Ramana Murthy V Kolapalli · pp. 587–593Original ArticleSame type: Article